Haemonetics (NYSE:HAE) CAO Farris Maryanne Maunsell Sells 836 Shares of Stock

Haemonetics Corporation (NYSE:HAE) CAO Farris Maryanne Maunsell sold 836 shares of the company’s stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $120.99, for a total value of $101,147.64. Following the completion of the sale, the chief accounting officer directly owned 5,828 shares of the company’s stock, valued at approximately $705,129.72. This trade represents a 12.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Haemonetics Trading Up 0.4%

Shares of NYSE:HAE traded up $0.45 during mid-day trading on Friday, reaching $123.16. The stock had a trading volume of 439,677 shares, compared to its average volume of 686,811. The firm has a market cap of $5.61 billion, a PE ratio of 55.23, a price-to-earnings-growth ratio of 2.45 and a beta of 0.63. The firm has a 50 day simple moving average of $113.34 and a two-hundred day simple moving average of $81.36. The company has a current ratio of 2.84, a quick ratio of 1.83 and a debt-to-equity ratio of 1.24. Haemonetics Corporation has a twelve month low of $51.00 and a twelve month high of $132.00.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.06. The business had revenue of $357.76 million for the quarter, compared to analyst estimates of $345.15 million. Haemonetics had a net margin of 7.52% and a return on equity of 27.42%. Haemonetics’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the firm earned $1.27 EPS. On average, research analysts predict that Haemonetics Corporation will post 5.32 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on HAE. Wall Street Zen lowered shares of Haemonetics from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 7th. Raymond James Financial upped their price objective on shares of Haemonetics from $105.00 to $125.00 and gave the company an “outperform” rating in a research report on Thursday, September 3rd. JPMorgan Chase & Co. raised their price objective on Haemonetics from $62.00 to $86.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. BTIG Research lifted their target price on Haemonetics from $130.00 to $142.00 and gave the stock a “buy” rating in a report on Thursday, November 5th. Finally, Citigroup boosted their target price on Haemonetics from $123.00 to $149.00 and gave the company a “buy” rating in a research note on Friday, November 6th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $129.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Bessemer Group Inc. raised its position in Haemonetics by 53.7% in the 3rd quarter. Bessemer Group Inc. now owns 269 shares of the medical instruments supplier’s stock valued at $28,000 after buying an additional 94 shares during the last quarter. Fortitude Family Office LLC boosted its position in Haemonetics by 104.5% during the 3rd quarter. Fortitude Family Office LLC now owns 272 shares of the medical instruments supplier’s stock worth $29,000 after acquiring an additional 139 shares during the last quarter. Kelleher Financial Advisors acquired a new position in Haemonetics during the 2nd quarter worth approximately $38,000. Root Financial Partners LLC acquired a new position in Haemonetics during the 3rd quarter worth approximately $40,000. Finally, Northwestern Mutual Wealth Management Co. bought a new position in shares of Haemonetics during the 2nd quarter worth approximately $44,000. 99.67% of the stock is owned by institutional investors and hedge funds.

Haemonetics Company Profile

Haemonetics Corporation is a global medical technology company focused on blood and plasma collection, processing and management. Its products and services are used by plasma collection organizations, blood centers and hospitals. The company provides automated plasma collection systems and related software and supplies, as well as technologies for collecting and processing blood components. Its hospital offerings include devices for surgical blood salvage and tools that help clinicians assess blood clotting and guide transfusion decisions.